OTCMKTS:GNWSFGeneNews Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GeneNews Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.05 +0.01 (+28.17 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.04Now: $0.05▼$0.0550-Day Range$0.04MA: $0.06▼$0.0952-Week Range$0.02Now: $0.05▼$0.14Volume40,400 shsAverage Volume19,327 shsMarket Capitalization$14.46 millionP/E RatioN/ADividend YieldN/ABeta3.09 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GeneNews. Previous Next 2.6 Community Rank Outperform VotesGeneNews has received 71 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGeneNews has received 64 “underperform” votes. (Add your “underperform” vote.)Community SentimentGeneNews has received 52.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote “Outperform” if you believe GNWSF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNWSF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGeneNews does not currently pay a dividend.Dividend GrowthGeneNews does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeneNews insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNWSF Previous Symbol CUSIPN/A CIKN/A Webwww.stagezerolifesciences.com Phone905-209-2030Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$140,000.00 Price / Sales103.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-2.28Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,480,000.00 Net Margins-343.30% Return on EquityN/A Return on Assets-78.35%Miscellaneous Employees16 Outstanding Shares317,740,000Market Cap$14.46 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable OTC:GNWSF Rates by TradingView Receive GNWSF News and Ratings via Email Sign-up to receive the latest news and ratings for GNWSF and its competitors with MarketBeat's FREE daily newsletter. GeneNews (OTCMKTS:GNWSF) Frequently Asked Questions How has GeneNews' stock been impacted by COVID-19 (Coronavirus)? GeneNews' stock was trading at $0.0266 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNWSF shares have increased by 71.1% and is now trading at $0.0455. View which stocks have been most impacted by Coronavirus. When is GeneNews' next earnings date? GeneNews is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for GeneNews. Has GeneNews been receiving favorable news coverage? Headlines about GNWSF stock have trended negative on Sunday, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GeneNews earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days. View the latest news about GeneNews. Who are some of GeneNews' key competitors? Some companies that are related to GeneNews include Trinity Biotech (TRIB), ImmuCell (ICCC), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ). View all competitors. Who are GeneNews' key executives? GeneNews' management team includes the following people: Mr. James R. Howard-Tripp, Exec. Chairman & CEOMs. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDLProf. Choong-Chin Liew Ph.D., Co-FounderMr. Warren Whitehead, Chief Accountant (Age 67)Mr. David Suria, Sr. Scientist What is GeneNews' stock symbol? GeneNews trades on the OTCMKTS under the ticker symbol "GNWSF." How do I buy shares of GeneNews? Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GeneNews' stock price today? One share of GNWSF stock can currently be purchased for approximately $0.05. How big of a company is GeneNews? GeneNews has a market capitalization of $14.46 million and generates $140,000.00 in revenue each year. GeneNews employs 16 workers across the globe. What is GeneNews' official website? The official website for GeneNews is www.stagezerolifesciences.com. How can I contact GeneNews? GeneNews' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
